Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
0.7790
Dollar change
+0.0090
Percentage change
1.17
%
Index- P/E- EPS (ttm)-2.11 Insider Own20.95% Shs Outstand11.63M Perf Week-1.25%
Market Cap10.61M Forward P/E- EPS next Y-0.07 Insider Trans0.00% Shs Float10.77M Perf Month15.07%
Income-24.07M PEG- EPS next Q-0.01 Inst Own4.25% Short Float1.80% Perf Quarter47.01%
Sales0.00M P/S- EPS this Y41.75% Inst Trans-0.73% Short Ratio0.81 Perf Half Y-14.40%
Book/sh1.45 P/B0.54 EPS next Y-25.00% ROA-73.83% Short Interest0.19M Perf Year-51.31%
Cash/sh1.46 P/C0.53 EPS next 5Y- ROE-90.47% 52W Range0.42 - 1.89 Perf YTD52.75%
Dividend Est.- P/FCF- EPS past 5Y-13.49% ROI-139.06% 52W High-58.78% Beta0.36
Dividend TTM- Quick Ratio4.16 Sales past 5Y0.00% Gross Margin- 52W Low85.48% ATR (14)0.06
Dividend Ex-Date- Current Ratio4.32 EPS Y/Y TTM11.48% Oper. Margin0.00% RSI (14)56.65 Volatility8.88% 8.21%
Employees37 Debt/Eq0.02 Sales Y/Y TTM- Profit Margin- Recom2.00 Target Price7.00
Option/ShortNo / Yes LT Debt/Eq0.02 EPS Q/Q62.58% Payout- Rel Volume0.12 Prev Close0.77
Sales Surprise- EPS Surprise35.00% Sales Q/Q- EarningsMar 07 BMO Avg Volume240.52K Price0.78
SMA202.35% SMA5017.73% SMA200-10.48% Trades Volume28,500 Change1.17%
Date Action Analyst Rating Change Price Target Change
Dec-19-23Resumed ROTH MKM Buy $7
Mar-25-24 07:06AM
Mar-07-24 12:53PM
07:00AM
Mar-05-24 07:00AM
Feb-20-24 07:00AM
07:00AM Loading…
Feb-14-24 07:00AM
Feb-05-24 07:00AM
Jan-30-24 07:00AM
Jan-03-24 07:00AM
Nov-16-23 07:00AM
Nov-15-23 07:00AM
Nov-13-23 08:00AM
Nov-09-23 08:00AM
Nov-06-23 04:15PM
Oct-30-23 07:00AM
07:00AM Loading…
Oct-26-23 07:00AM
Sep-28-23 07:00AM
Aug-29-23 07:00AM
Aug-14-23 08:00AM
Jun-28-23 07:00AM
Jun-26-23 07:00AM
Jun-21-23 07:00AM
Jun-05-23 07:00AM
Jun-02-23 09:00AM
May-24-23 07:00AM
May-11-23 06:00AM
Apr-26-23 07:00AM
Apr-19-23 07:00AM
Apr-12-23 07:00AM
Mar-29-23 08:30AM
07:00AM Loading…
Mar-17-23 07:00AM
Mar-06-23 07:00AM
Feb-21-23 07:00AM
Jan-03-23 07:00AM
Dec-21-22 07:00AM
Nov-30-22 07:00AM
Nov-11-22 06:00AM
Nov-09-22 08:00AM
Nov-01-22 07:00AM
Oct-28-22 07:00AM
Aug-12-22 06:00AM
06:00AM
Aug-01-22 07:00AM
Jun-27-22 08:00AM
Jun-21-22 07:00AM
Jun-09-22 09:00AM
Jun-02-22 07:00AM
May-18-22 07:00AM
May-12-22 06:00AM
May-04-22 07:00AM
Mar-23-22 07:00AM
Mar-14-22 08:00AM
Mar-09-22 06:00AM
Mar-02-22 08:00AM
Feb-10-22 08:00AM
Jan-04-22 07:00AM
Dec-20-21 08:00AM
Dec-16-21 04:05PM
Dec-03-21 08:00AM
Dec-02-21 07:00AM
Nov-23-21 05:34AM
Nov-12-21 07:00AM
Nov-10-21 07:00AM
Nov-09-21 07:00AM
Nov-08-21 07:00AM
Oct-26-21 08:53AM
Oct-15-21 11:42AM
Sep-27-21 07:00AM
Sep-02-21 07:00AM
Sep-01-21 07:18AM
Aug-13-21 08:00AM
Jun-23-21 08:30AM
08:30AM
Jun-17-21 02:44AM
Jun-10-21 07:00AM
May-17-21 08:30PM
May-13-21 09:25AM
May-12-21 07:00AM
Apr-26-21 06:30AM
Mar-29-21 09:00AM
Mar-22-21 07:00AM
Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. It discovers and develops therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company was founded by Adi Mor on September 22, 2011 and is headquartered in Tel Aviv, Israel.